We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-15.55%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.4B
AUM Growth
-$496M
Cap. Flow
+$87.6M
Cap. Flow %
3.65%
Top 10 Hldgs %
69.51%
Holding
38
New
3
Increased
9
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$54.7M
2
PCRX icon
Pacira BioSciences
PCRX
+$47.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$32.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.8M
5
QURE icon
uniQure
QURE
+$21.1M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$92.7M
2
MDCO
Medicines Co
MDCO
+$22.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.6M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.66M

Sector Composition

Rank Sector Weight
1 Healthcare 87.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$292M 12.19%
3,750,000
-112,500
-3% -$10.6M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$278M 11.62%
21,000,000
– –
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.03B
$193M 8.05%
10,601,039
-151,546
-1% -$3.35M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.6B
$190M 7.92%
1,970,000
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$164M 6.85%
2,437,100
+322,100
+15% +$24.8M
AMRN
6
Amarin Corp
AMRN
$300M
$129M 5.39%
426,000
+51,000
+14% +$17.8M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.64B
$126M 5.27%
1,678,000
+278,000
+20% +$32.8M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$109M 4.54%
4,000,000
– –
ARGX icon
9
argenx
ARGX
$54.9B
$95.2M 3.97%
835,000
-5,000
-0.6% -$676K
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$89M 3.71%
11,100,000
+1,100,000
+11% +$11.9M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$81M 3.38%
1,552,700
+177,700
+13% +$9.45M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$75.1M 3.13%
1,875,000
-150,000
-7% -$6.91M
ATNX
13
DELISTED
Athenex, Inc. Common Stock
ATNX
$71.7M 2.99%
294,500
+64,250
+28% +$21M
TCDA
14
DELISTED
Tricida, Inc. Common Stock
TCDA
$67.9M 2.83%
2,200,000
– –
PCRX icon
15
Pacira BioSciences
PCRX
$1.04B
$60.9M 2.54%
1,600,000
+1,200,000
+300% +$47.9M
KPTI icon
16
Karyopharm Therapeutics
KPTI
$155M
$58.2M 2.43%
+403,333
New +$54.7M
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$48.5M 2.02%
1,000,000
+50,000
+5% +$2.61M
ACAD icon
18
Acadia Pharmaceuticals
ACAD
$4.45B
$31.9M 1.33%
887,500
-437,500
-33% -$13.3M
BDSI
19
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$31.3M 1.3%
7,424,867
– –
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.4B
$31M 1.29%
360,000
– –
ALLO icon
21
Allogene Therapeutics
ALLO
$607M
$30.8M 1.28%
1,128,594
– –
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
$23.2M 0.97%
425,000
+75,000
+21% +$8.45M
PTCT icon
23
PTC Therapeutics
PTCT
$6.12B
$23.1M 0.97%
684,000
– –
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.16B
$21.6M 0.9%
2,400,000
– –
MDCO
25
DELISTED
Medicines Co
MDCO
$18.6M 0.78%
371,623
-553,377
-60% -$22.1M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Avoro Capital Advisors held 38 positions worth $2.4B, down 17% from $2.89B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors deployed $87.6M of net new capital in Q3 2019, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was Karyopharm Therapeutics: 403,333 shares worth $58.2M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Medicines Co, an estimated $22.1M trimmed.

  • Avoro Capital Advisors's largest Q3 2019 buy was Karyopharm Therapeutics: 403,333 shares worth $58.2M.
  • Avoro Capital Advisors added most to Pacira BioSciences in Q3 2019, an estimated $47.9M increase.
  • Avoro Capital Advisors's biggest Q3 2019 reduction was Medicines Co, cutting an estimated $22.1M.
  • Avoro Capital Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $92.7M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $2.4B portfolio in Q3 2019.
  • Avoro Capital Advisors opened 3 new positions and closed 5 in Q3 2019.
  • Avoro Capital Advisors's portfolio value fell 17% quarter-over-quarter to $2.4B.

Based on Avoro Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.